Prevention of transfusion-associated cytomegalovirus infection. Practice parameter. American Society of Clinical Pathologists.
This practice guideline represents the opinions and recommendations of the author(s), the American Society of Clinical Pathologists (ASCP) Practice Parameters Committee and the ASCP Board of Directors regarding the appropriate strategies for each clinical condition or laboratory test discussed in this guideline. This guideline is designed primarily as an educational resource for physicians in the provision of quality medical services. Adherence to this guideline is completely voluntary and does not necessarily assure a successful medical treatment or result. This practice guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures or tests that are reasonably directed to obtaining the same results. The physician should apply his or her own professional judgment to the unique clinical circumstances presented by the particular procedure or test. Physicians are encouraged to document the reasons for whatever procedure or test they use (whether or not in conformance with this guideline). Physicians should also take care to consider other medical and scientific advances that are available after the date of adoption of this guideline. This practice guideline was developed exclusively for the purposes set forth above and not for use in connection with matters involving reimbursement, credentialing, or utilization review.
Przepiorka
D
D
Department of Hematology, University of Texas M.D. Anderson Cancer Center, Houston, USA.
LeParc
G F
GF
Werch
J
J
Lichtiger
B
B
D000328:Adult; D003362:Cost-Benefit Analysis; D003586:Cytomegalovirus Infections / Q000517:prevention & control* / Q000635:transmission; D017707:Erythrocyte Transfusion / Q000009:adverse effects* / Q000191:economics; D005374:Filtration; D006305:Health Status Indicators; D006801:Humans; D016867:Immunocompromised Host; D007231:Infant, Newborn; D008403:Mass Screening / Q000379:methods; D017713:Platelet Transfusion / Q000009:adverse effects* / Q000191:economics; D011322:Primary Prevention / Q000379:methods; D012955:Societies, Medical; D014019:Tissue Donors; D014481:United States